2023, Aeschbacher, Marc, Legena, Valeria, Gerber, Aurona, Hinkelmann, Knut

2020, Schulte, Volker, Verkuil, Arie Hans, Meyer, Rolf, Aeschbacher, Marc

2020, Verkuil, Arie Hans, Meyer, Rolf, Aeschbacher, Marc

2021, Aeschbacher, Marc, Legena, Valeria, Schulte, Volker, Steinebach, Christoph, Veth, Klaske

2020, Kabous, Laila, Verkuil, Arie Hans, Meyer, Rolf, Aeschbacher, Marc

Founded in 2019, Perseo Pharma is a preclinical-stage biotech company with a unique asset for the development of enzyme therapies. Perseo Pharma possesses an innovative and proprietary enzyme shielding technology. Founded as independent spin-off of INOFEA AG, the company focuses on therapeutic enzymes for the treatment of cancer and rare genetic diseases. Over the past three decades, 30 therapeutic enzymes have been approved by EMA and FDA generating yearly 40bn. Therapeutic enzymes address a wide variety of indications, ranging from rare genetic diseases (enzyme replacement therapies) to oncology (key tumor-element depletion therapies). This offers biotech companies different opportunities and application fields for further development of enzyme therapeutics. The goal of this research is to analyze the case based on the 7-key model and provide recommendations on the financing opportunities available for Perseo pharma.

2020, Meyer, Rolf, Verkuil, Arie Hans, Aeschbacher, Marc

2020, Eisenbart, Barbara, Verkuil, Arie Hans, Meyer, Rolf, Aeschbacher, Marc

2020, Aeschbacher, Marc, Verkuil, Arie Hans, Meyer, Rolf, Aeschbacher, Marc